Stock Alert for ADVENTRX Pharmaceuticals Inc. (ANX)
ADVENTRX Pharmaceuticals Inc. (AMEX: ANX)
ADVENTRX Pharmaceuticals Inc. (ANX) is a development-stage biopharmaceutical company. The Company’s business is focused on in-licensing, developing and commercializing product candidates for the treatment of cancer. Its lead product candidates, ANX-530 and ANX-514, are emulsion formulations of marketed chemotherapy drugs. ANX is focused primarily on evaluating strategic options, including the sale or exclusive license of one or more of its product candidate programs, a strategic business merger and other similar transactions. In October 2008, ANX announced that it had discontinued active work on all product candidates other than ANX-530 and ANX-514. Its wholly owned subsidiaries include SD Pharmaceuticals Inc. (SDP) and ANX (Europe) Ltd.
The Company was founded in 1995 is based in San Diego, California.
| Share Statistics (23-Jun-10) | FY
2007 |
FY
2008 |
%
Chg |
Q4 2008 | Q4 2009 | %
Chg |
||
| Symbol | ANX | Revenue, $Mn | 0.5M | 0.5M | 0.0% | 0.0M | 0.0M | 0.0% |
| Current price | $1.82 | Gross marg. | n/a | n/a | n/a | n/a | n/a | n/a |
| 52wk Range: | $13.00-1.77 | Oper. margin | -4862% | -5462% | 12.3% | -n/m | -n/m | n/a |
| Avg Vol (3m): | 571,029 | Net margin | -44200% | -53200% | 20.4% | -n/m | -n/m | n/a |
| Market Cap. | 18.73M | |||||||
| Dil. Shares Outst. | 14.3M | EPS, $ | -6.25 | -7.50 | 20.0% | -2.00 | -1.00 | 50.0% |
Source: Reuters.com, SEC Filings.
Financial Summary
ANX’s net loss applicable to common stock for the first quarter of 2010 was $4.9 million, or $0.48 per share, compared to a net loss applicable to common stock of $3.2 million, or $0.87 per share, for the same period in 2009. Included in the net loss applicable to common stock for the first quarter of 2010 was a non-cash, deemed dividend expense of $2.5 million incurred in connection with the Company’s January 2010 equity financing.
Research and development (R&D) expenses for the first quarter of 2010 were $1.2 million, a decrease of $0.4 million, or 25%, compared to $1.6 million for the same period in 2009. The decrease primarily was due to a decrease in personnel costs attributable to lower headcount in 2010 and the completion of severance payments associated with the Company’s 2009 and 2008 workforce reductions by June 30, 2009, a decrease in external bioequivalence trial expenses associated with the completion of patient enrollment in the ANX-514 bioequivalence study in the first quarter of 2009, offset by increased expenses in research-related manufacturing for ANX-514 and increase in costs attributable to consulting services related to Exelbine and ANX-514.
Selling, general and administrative (SG&A) expenses for the first quarter of 2010 were $1.2 million, a decrease of $0.6 million, or 34%, compared to $1.8 million for the same period in 2009. The decrease primarily was due to a decrease in personnel costs attributable to lower headcount in 2010 as a result of the Company’s workforce reductions in 2009.
Balance Sheet Highlights
As of March 31, 2010, the Company had cash of $19.8 million and stockholders’ equity of $18.8 million.
Reverse Stock Split
On April 23, 2010, ANX effected a 1-for-25 reverse split of its outstanding shares of common stock. All share and per-share information in this press release reflect the reverse stock split. Share and per-share information related to dates or periods prior to April 23, 2010, have been restated to reflect retrospective application of the reverse stock split.
| Financial Strength (23-Jun-2010) | Company | Industry | Sector | S&P 500 |
| Quick Ratio (MRQ) | 16.06 | 2.08 | 2.10 | 0.81 |
| Current Ratio (MRQ) | 16.06 | 2.44 | 2.51 | 0.97 |
| Long-Term Debt to Equity(MRQ) | 0.00 | 7.95 | 18.68 | 133.64 |
| Total Debt to Equity (MRQ) | 0.00 | 10.93 | 24.07 | 199.18 |
Source: Reuters.com, SEC Filings.
Analyst Consensus
| Buy | Outperform | Hold | Underperform | Sell | No Opinion |
This is the consensus forecast amongst one polled investment analysts. Against the ADVENTRX Pharmaceuticals Inc company.
| Analyst Detail | Buy | Outperform | Hold | Underperform | Sell | No Opinion |
| Latest | 0 | 1 | 0 | 0 | 0 | 0 |
| 4 weeks ago | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 months ago | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 months ago | 0 | 0 | 0 | 0 | 0 | 0 |
| Last year | 0 | 0 | 0 | 0 | 0 | 0 |
The one analyst offering a 12 month price target expects ANX share price to rise to 6.00 in the next year from the last price of 1.82.
Source: www.ft.com
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
| SALES (in millions) | |||||
| Year Ending Dec-11 | 1 | 0.36 | 0.36 | 0.36 | – |
| EARNINGS (per share) | |||||
| Quarter Ending Jun-10 | 1 | -0.51 | -0.51 | -0.51 | – |
| Quarter Ending Sep-10 | 1 | -0.47 | -0.47 | -0.47 | – |
| Year Ending Dec-10 | 1 | -1.77 | -1.77 | -1.77 | – |
| Year Ending Dec-11 | 1 | -1.30 | -1.30 | -1.30 | – |
Source: http://www.reuters.com/finance/stocks/financialHighlights?symbol=ANX
Investment Highlights
ANX recently announced that it has granted Theragence Inc. exclusive, worldwide rights under its know-how to develop, make, use and sell 5,10-methylenetetrahydrofolate, also known as ANX-510 or CoFactor. Under the terms of their agreement, Theragence will use commercially reasonably efforts to research, develop and commercialize licensed products. ANX will receive royalties on net sales of licensed products and up to approximately $30 million in commercial milestones based on aggregate gross sales of licensed products in the United States, European Union and Japan.
In October 2007, ANX reported the results of a Phase 2b study in which CoFactor, in combination with 5-fluorouracil, did not demonstrate statistically significant improved safety in the trial’s primary endpoint. In November 2007, ANX discontinued enrolling patients in its Phase 3 clinical trial of CoFactor for the treatment of metastatic colorectal cancer and, in October 2008, ANX discontinued active work on its CoFactor program.
Lead Product Candidates
ANX is currently focused on developing and seeking regulatory approval for two late-stage product candidates, ANX-530 (vinorelbine injectable emulsion), or Exelbine™, and ANX-514 (docetaxel lyophilized emulsion for injection), which are novel emulsion formulations of currently marketed chemotherapy drugs. ANX believes Exelbine and ANX-514 may improve the safety of and have greater commercial potential than the currently marketed reference products, Navelbine® (vinorelbine tartrate) Injection and Taxotere® (docetaxel) Injection Concentrate, respectively, by:
- Reducing the incidence and severity of adverse effects; and
- Improving their pharmacoeconomics and convenience to healthcare practitioners and patients.
Reformulating existing pharmaceutical products is an increasingly common product lifecycle-management technique. Finding new markets for and ways to modify and improve existing products is often an essential element of pharmaceutical companies’ efforts to innovate and improve treatment outcomes in the context of patent expirations and competitive pressures.
Navelbine and Taxotere are intravenously-injected chemotherapy drugs commonly used to treat solid tumors. ANX believes the current formulations of these drugs have limitations, such as phlebitis, erythema, hypersensitivity reactions and fluid retention that present opportunities for improvement. The Company is developing novel ways to formulate the active ingredient underlying each of these drugs that it believes will improve their safety profiles without adversely affecting efficacy. In addition, ANX believes its formulations may provide benefits to patients and practitioners that do not manifest themselves in traditional measures of safety or efficacy.
ANX actively seeks new partnership opportunities to expand and improve its development and commercialization efforts. The Company is committed to creating relationships that are beneficial to both the goals of its partners and goals of the Company.
Source: http://www.adventrx.com/
Technical Analysis
Source: http://stockcharts.com
ANX is below its 13-day moving average. This bearish sign is even more significant because the moving average is also trending lower.
ANX is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.
ANX’s MACD is currently indicating a weak bullish signal. Although the MACD is trending above the signal line, the indicator is still below zero, which suggests that the underlying moving averages are bearish.
Comparative Analysis
| Company Name | Ticker | Price per | Mrkt. Cap. | P/E | P/S | ||
| Jun-23-2010 | symbol | Share, $ | $ Mn | 2010 | 2011 | 2010 | 2011 |
| Telik Inc. | TELK | 0.77 | 41.21M | n/a | n/a | n/a | n/a |
| SuperGen Inc. | SUPG | 2.11 | 127.19M | 23.79 | n/a | 3.23 | n/a |
| Caraco Pharmaceuticals Inc. | CPD | 4.21 | 164.57M | n/a | n/a | 0.74 | n/a |
| Drug Manufacturers Median | 110.99M | n/a | n/a | 1.98 | n/a | ||
| ADVENTRX Pharmaceuticals Inc. | ANX | 1.82 | 18.73M | n/a | n/a | 63.80 | n/a |
Source: Thomson Financial
Insider Trading Activity
| NET SHARES PURCHASE ACTIVITY
Inside Purchases – Last 6 Months |
||
| Shares | Transaction | |
| Purchases | n/a | 0 |
| Sales | n/a | 0 |
| Net Shares Purchased (Sold) | n/a | 0 |
| Total Insider Shares Held | 177.38K | n/a |
| % Net Shares Purchased (Sold) | 0.0% | n/a |
| Net Institutional Purchases — Prior Qtr to Latest Qtr | |
| Shares | |
| Net Shares Purchased (Sold) | (36,532) |
| % Change in Institutional Shares Held | (15.1%) |
Source: Yahoo Finance
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.
Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.
We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.
To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).
We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov and FINRA at http://www.finra.org.
